# A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma

> **NCT05584306** · PHASE1 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** 610 30mg group
- **DRUG:** 610 100mg group
- **DRUG:** 610 300mg group
- **OTHER:** Placebo 30mg group
- **OTHER:** Placebo 100mg group
- **OTHER:** Placebo 300mg group

## Key facts

- **NCT ID:** NCT05584306
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-06
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05584306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05584306, "A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05584306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*